

Global Castrate-resistant Prostate Cancer Market Size study, by Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy) and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G3C0CB10584AEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G3C0CB10584AEN

Abstracts

Global Castrate-resistant Prostate Cancer (CRPC) Market is valued at approximately USD 11.91 billion in 2023 and is anticipated to grow with a compound annual growth rate (CAGR) of 8.70% over the forecast period 2024 to 2032. Castrate-resistant prostate cancer represents one of the most challenging forms of prostate malignancy, as it progresses despite androgen deprivation therapy (ADT), which typically halts tumor growth. The treatment paradigm for CRPC has dramatically evolved in recent years, transitioning from conventional hormone therapy to a multimodal arsenal of chemotherapy, targeted immunotherapies, next-generation hormonal agents, and radiopharmaceuticals. This clinical shift is rooted in robust molecular research and the increasing adoption of personalized oncology pathways, which are helping redefine patient outcomes in advanced prostate cancer cases.

Rising incidence rates, fueled by aging populations and improved diagnostic protocols, are significantly driving market expansion. The development and commercialization of androgen receptor inhibitors like enzalutamide and abiraterone, as well as immune checkpoint inhibitors, have broadened therapeutic horizons. Additionally, innovative combinations of radiotherapy with systemic treatments are creating more durable responses in metastatic cases. However, despite the promising clinical results, resistance mechanisms, high drug costs, and disparities in treatment access continue to pose substantial challenges. The focus is now shifting toward identifying biomarkers for early resistance and leveraging AI-driven decision-support systems for therapy optimization.

A surge in investments from both private biopharma and public institutions is bolstering clinical trials across a spectrum of therapeutic classes. Notably, immunotherapy is emerging as a major frontier, with vaccine-based and T-cell-mediated therapies under accelerated development. Furthermore, radioligand therapies targeting prostate-specific membrane antigen (PSMA) are gaining momentum and are expected to become a cornerstone in advanced CRPC management. These advancements, combined with patient-tailored regimens and decentralized clinical approaches, are cultivating a highly innovative and patient-centric landscape in the CRPC market.

North America dominates the CRPC market due to its sophisticated oncology infrastructure, favorable reimbursement scenarios, and rapid uptake of novel therapies. Europe also maintains a strong presence, with ongoing regulatory support and strategic collaborations between academia and biotech firms. Meanwhile, the Asia Pacific region is set to exhibit the fastest growth trajectory, driven by increasing prostate cancer burden, rising healthcare expenditure, and accelerated regulatory approvals in nations like China, India, and Japan. Latin America and the Middle East & Africa are gradually integrating CRPC management frameworks, supported by expanded healthcare access and international aid programs.

Major market player included in this report are:

Johnson & Johnson Services, Inc.

Bayer AG

Pfizer Inc.

Astellas Pharma Inc.

Sanofi S.A.

Novartis AG

AstraZeneca PLC

Merck & Co., Inc.

Amgen Inc.

Clovis Oncology, Inc.

Bristol-Myers Squibb Company

Myovant Sciences GmbH

Endo International plc

Tolmar Inc.

AbbVie Inc.

The detailed segments and sub-segment of the market are explained below:

By Therapy

Chemotherapy

Hormonal Therapy

Immunotherapy

Radiotherapy

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year – 2022

Base Year – 2023

Forecast Period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032

Annualized revenues and regional level analysis for each market segment

Detailed analysis of geographical landscape with country-level analysis of major regions

Competitive landscape with information on major players in the market

Analysis of key business strategies and recommendations on future market approach

Analysis of competitive structure of the market

Demand side and supply side analysis of the market

Contents

CHAPTER 1. GLOBAL CASTRATE-RESISTANT PROSTATE CANCER MARKET EXECUTIVE SUMMARY

- 1.1. Global CRPC Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Therapy
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL CASTRATE-RESISTANT PROSTATE CANCER MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Patient Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL CASTRATE-RESISTANT PROSTATE CANCER MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Incidence Among Aging Populations
- 3.1.2. Advances in Next-Generation Hormonal and Targeted Therapies
- 3.1.3. Personalized Oncology and Molecular Diagnostics

3.2. Market Challenges

- 3.2.1. Emergence of Drug Resistance Mechanisms
- 3.2.2. High Cost of Novel Therapeutics
- 3.2.3. Disparities in Global Treatment Access

3.3. Market Opportunities

- 3.3.1. Growth of Immunotherapy and Vaccine-based Approaches
- 3.3.2. Expansion of Radioligand Therapies (PSMA-Targeted)
- 3.3.3. AI-Driven Treatment Optimization

CHAPTER 4. GLOBAL CASTRATE-RESISTANT PROSTATE CANCER MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL CASTRATE-RESISTANT PROSTATE CANCER MARKET SIZE & FORECASTS BY THERAPY, 2022–2032

- 5.1. Segment Dashboard
- 5.2. Chemotherapy Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.3. Hormonal Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.4. Immunotherapy Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.5. Radiotherapy Revenue Trend Analysis, 2022 & 2032 (USD Million)

CHAPTER 6. GLOBAL CASTRATE-RESISTANT PROSTATE CANCER MARKET SIZE & FORECASTS BY REGION, 2022–2032

- 6.1. North America Market
 - 6.1.1. U.S. Market
 - 6.1.1.1. Therapy Breakdown & Forecasts, 2022–2032
 - 6.1.2. Canada Market
- 6.2. Europe Market
 - 6.2.1. UK Market
 - 6.2.2. Germany Market
 - 6.2.3. France Market
 - 6.2.4. Spain Market
 - 6.2.5. Italy Market
 - 6.2.6. Rest of Europe Market
- 6.3. Asia Pacific Market
 - 6.3.1. China Market
 - 6.3.2. India Market
 - 6.3.3. Japan Market
 - 6.3.4. Australia Market
 - 6.3.5. South Korea Market
 - 6.3.6. Rest of Asia Pacific Market
- 6.4. Latin America Market
 - 6.4.1. Brazil Market
 - 6.4.2. Mexico Market
 - 6.4.3. Rest of Latin America Market
- 6.5. Middle East & Africa Market
 - 6.5.1. Saudi Arabia Market
 - 6.5.2. South Africa Market
 - 6.5.3. Rest of Middle East & Africa Market

CHAPTER 7. COMPETITIVE INTELLIGENCE

- 7.1. Key Company SWOT Analysis
 - 7.1.1. Johnson & Johnson Services, Inc.
 - 7.1.2. Bayer AG
 - 7.1.3. Pfizer Inc.
- 7.2. Top Market Strategies
- 7.3. Company Profiles
 - 7.3.1. Johnson & Johnson Services, Inc.
 - 7.3.1.1. Key Information
 - 7.3.1.2. Overview
 - 7.3.1.3. Financial (Subject to Data Availability)
 - 7.3.1.4. Product Summary
 - 7.3.1.5. Market Strategies
 - 7.3.2. Bayer AG
 - 7.3.3. Pfizer Inc.
 - 7.3.4. Astellas Pharma Inc.
 - 7.3.5. Sanofi S.A.
 - 7.3.6. Novartis AG
 - 7.3.7. AstraZeneca PLC
 - 7.3.8. Merck & Co., Inc.
 - 7.3.9. Amgen Inc.
 - 7.3.10. Clovis Oncology, Inc.
 - 7.3.11. Bristol-Myers Squibb Company
 - 7.3.12. Myovant Sciences GmbH
 - 7.3.13. Endo International plc
 - 7.3.14. Tolmar Inc.
 - 7.3.15. AbbVie Inc.

CHAPTER 8. RESEARCH PROCESS

- 8.1. Research Process
 - 8.1.1. Data Mining
 - 8.1.2. Analysis
 - 8.1.3. Market Estimation
 - 8.1.4. Validation
 - 8.1.5. Publishing
- 8.2. Research Attributes

I would like to order

Product name: Global Castrate-resistant Prostate Cancer Market Size study, by Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy) and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G3C0CB10584AEN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3C0CB10584AEN.html>